Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) closed at $25.0 up 2.21% from its previous closing price of $24.46. In other words, the price has increased by $2.21 from its previous closing price. On the day, 1.08 million shares were traded. CNTA stock price reached its highest trading level at $25.31 during the session, while it also had its lowest trading level at $24.61.
Ratios:
For a deeper understanding of Centessa Pharmaceuticals plc ADR’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.12 and its Current Ratio is at 10.12. In the meantime, Its Debt-to-Equity ratio is 0.34 whereas as Long-Term Debt/Eq ratio is at 0.34.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Stephens on October 28, 2025, initiated with a Overweight rating and assigned the stock a target price of $35.
On September 03, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $31.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 27 ’25 when Accardi Mario Alberto sold 8,000 shares for $25.00 per share. The transaction valued at 200,000 led to the insider holds 194,394 shares of the business.
Accardi Mario Alberto bought 8,000 shares of CNTA for $200,000 on Oct 27 ’25. On Oct 15 ’25, another insider, HUSSAIN IQBAL J, who serves as the General Counsel of the company, sold 6,000 shares for $22.41 each. As a result, the insider received 134,439 and left with 105,386 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CNTA now has a Market Capitalization of 3351835904 and an Enterprise Value of 3219252992. For the stock, the TTM Price-to-Sale (P/S) ratio is 222.29 while its Price-to-Book (P/B) ratio in mrq is 9.71. Its current Enterprise Value per Revenue stands at 214.617 whereas that against EBITDA is -15.619.
Stock Price History:
The Beta on a monthly basis for CNTA is 1.57, which has changed by 0.62094104 over the last 52 weeks, in comparison to a change of 0.18258524 over the same period for the S&P500. Over the past 52 weeks, CNTA has reached a high of $25.30, while it has fallen to a 52-week low of $9.60. The 50-Day Moving Average of the stock is 17.63%, while the 200-Day Moving Average is calculated to be 53.05%.
Shares Statistics:
For the past three months, CNTA has traded an average of 1.20M shares per day and 799350 over the past ten days. A total of 133.91M shares are outstanding, with a floating share count of 85.14M. Insiders hold about 36.42% of the company’s shares, while institutions hold 56.13% stake in the company. Shares short for CNTA as of 1760486400 were 5200791 with a Short Ratio of 4.33, compared to 1757894400 on 5512433. Therefore, it implies a Short% of Shares Outstanding of 5200791 and a Short% of Float of 4.5700002.
Earnings Estimates
. The current rating of Centessa Pharmaceuticals plc ADR (CNTA) reflects the combined expertise of 9.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.41, with high estimates of -$0.32 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$1.21 and -$1.46 for the fiscal current year, implying an average EPS of -$1.37. EPS for the following year is -$1.64, with 10.0 analysts recommending between -$1.36 and -$2.03.
Revenue Estimates
For the next quarter, 11 analysts are estimating revenue of $382.18k. There is a high estimate of $9.2M for the next quarter, whereas the lowest estimate is -$5M.
